Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer.
暂无分享,去创建一个
K Shimada | Mitsutoshi Nakamura | K. Shimada | N. Konishi | M. Nakamura | M Nakamura | E Ishida | N Konishi | E. Ishida
[1] B. Beattie,et al. Regulation of Erythropoietin-induced STAT Serine Phosphorylation by Distinct Mitogen-activated Protein Kinases* , 2002, The Journal of Biological Chemistry.
[2] F. Claessens,et al. The AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1 , 1999, Molecular and Cellular Biology.
[3] A. Bode,et al. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. , 2002, Cancer research.
[4] J. Isaacs,et al. Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.
[5] Mitsutoshi Nakamura,et al. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. , 2004, Carcinogenesis.
[6] Z. Hall. Cancer , 1906, The Hospital.
[7] R. Meacham,et al. Mitogen Activated Protein kinase signal transduction pathways in the prostate , 2004, Cell Communication and Signaling.
[8] B. Dérijard,et al. Cdc42 and PAK-mediated Signaling Leads to Jun Kinase and p38 Mitogen-activated Protein Kinase Activation (*) , 1995, The Journal of Biological Chemistry.
[9] J. Roth,et al. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells , 1999, Oncogene.
[10] K. L. Pierce,et al. Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.
[11] Chen Dong,et al. MAP kinases in the immune response. , 2002, Annual review of immunology.
[12] G. Romano,et al. Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. , 2000, Endocrinology.
[13] G Bartsch,et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.
[14] M. Landström,et al. 2-Methoxyestradiol-induced Apoptosis in Prostate Cancer Cells Requires Smad7* , 2005, Journal of Biological Chemistry.
[15] P. de Souza,et al. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. , 1997, British Journal of Cancer.
[16] D. Baltimore,et al. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. , 1998, Science.
[17] M. Peter,et al. Phosphorylation of FADD/ MORT1 at Serine 194 and Association with a 70-kDa Cell Cycle-Regulated Protein Kinase1 , 2000, The Journal of Immunology.
[18] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[19] J. Isaacs,et al. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.
[20] D. Tindall,et al. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. , 1997, Endocrinology.
[21] S. Katiyar,et al. Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. , 2004, Carcinogenesis.
[22] Mitsutoshi Nakamura,et al. Phosphorylation status of Fas‐associated death domain‐containing protein (FADD) is associated with prostate cancer progression , 2005, The Journal of pathology.
[23] J. Rhim,et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] S. Kambhampati,et al. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion , 2003, Oncogene.
[25] Y. Ip,et al. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.
[26] Michael E. Greenberg,et al. Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.
[27] K. Shimada,et al. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. , 2003, Carcinogenesis.
[28] M. Wilkinson,et al. SAPKs and transcription factors do the nucleocytoplasmic tango. , 1998, Genes & development.
[29] S. Chi,et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways1 , 2004 .
[30] J. R. Kim,et al. Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[32] P. Kaplan,et al. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer , 2003, The Prostate.
[33] D. Troyer,et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] S. Grösch,et al. Activation of c‐Jun‐N‐terminal‐kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] Nicholas Bruchovsky,et al. Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[36] W. Fang,et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. , 2004, Cancer letters.
[37] Teruhiko Fujii,et al. Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival Pathway* , 2003, Journal of Biological Chemistry.
[38] M. Gorospe,et al. Inhibition of c-Jun N-Terminal Kinase 2 Expression Suppresses Growth and Induces Apoptosis of Human Tumor Cells in a p53-Dependent Manner , 2000, Molecular and Cellular Biology.
[39] L. Zon,et al. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase , 1995, Nature.
[40] R. Katoh,et al. Poorly differentiated desmin-negative and vimentin-positive leiomyosarcoma of the stomach examined by the immunohistochemical and quick-freezing and deep-etching methods , 1998, Virchows Archiv.
[41] R. Davis,et al. Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.
[42] Shihua Sun,et al. Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.
[43] Teiji Wada,et al. Mitogen-activated protein kinases in apoptosis regulation , 2004, Oncogene.
[44] P. Walsh. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. , 2005, The Journal of urology.
[45] Minoru Takagi,et al. Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways , 1997, Science.
[46] H. Frierson,et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.
[47] L. Zon,et al. Cdc42Hs, but Not Rac1, Inhibits Serum-stimulated Cell Cycle Progression at G1/S through a Mechanism Requiring p38/RK* , 1997, The Journal of Biological Chemistry.
[48] E. Messing,et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. , 2002, Cancer research.
[49] G. Johnson,et al. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 , 1997, The EMBO journal.
[50] J. Aguirre-Ghiso,et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.
[51] J. Chant,et al. Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway , 1996, Current Biology.